Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:3672 |
Name | rhabdoid cancer |
Definition | A childhood kidney neoplasm that is located_in the kidney, liver, muscle, heart, lung, soft tissues, skin and central nervous system. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer urinary system cancer kidney cancer childhood kidney cancer rhabdoid cancer |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
SMARCB1 negative | Alvocidib | rhabdoid cancer | sensitive | detail... |
SMARCB1 negative | Fenretinide + Vorinostat | rhabdoid cancer | sensitive | detail... |
CDKN2A over exp SMARCB1 neg | Palbociclib | rhabdoid cancer | decreased response | detail... |
SMARCB1 negative | Palbociclib | rhabdoid cancer | sensitive | detail... |
SMARCB1 loss | Tazemetostat | rhabdoid cancer | sensitive | detail... |
SMARCB1 negative | Tazemetostat | rhabdoid cancer | predicted - sensitive | detail... |
SMARCA4 negative | Tazemetostat | rhabdoid cancer | predicted - sensitive | detail... |
SMARCB1 inact mut | N/A | rhabdoid cancer | not applicable | detail... |
SMARCB1 loss | Barasertib | rhabdoid cancer | sensitive | detail... |
RB1 del SMARCB1 loss | Seliciclib | rhabdoid cancer | sensitive | detail... |
RB1 del SMARCB1 loss | Alisertib | rhabdoid cancer | sensitive | detail... |
RB1 del SMARCB1 loss | Barasertib | rhabdoid cancer | sensitive | detail... |
RB1 del SMARCB1 loss | Tazemetostat | rhabdoid cancer | resistant | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00089245 | Phase I | Omburtamab I-131 | Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer | Terminated | USA | 0 |
NCT01331135 | Phase I | Sirolimus | Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors | Completed | USA | 0 |
NCT01747876 | Phase I | Ribociclib | Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma | Terminated | USA | GBR | FRA | DEU | AUS | 0 |
NCT02114229 | Phase II | Cisplatin + Cyclophosphamide + Methotrexate + Vincristine Sulfate Alisertib Alisertib + Carboplatin + Cyclophosphamide + Vincristine Sulfate Cyclophosphamide + Topotecan Alisertib + Carboplatin + Cyclophosphamide + Etoposide Carboplatin + Cyclophosphamide + Methotrexate + Vincristine Sulfate Alisertib + Cisplatin + Cyclophosphamide + Vincristine Sulfate | Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors (SJATRT) | Active, not recruiting | USA | 0 |
NCT02601937 | Phase I | Tazemetostat | A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma | Completed | USA | NLD | ITA | GBR | FRA | DNK | DEU | CAN | AUS | 0 |
NCT02601950 | Phase II | Tazemetostat | A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma | Completed | USA | ITA | GBR | FRA | DEU | CAN | BEL | AUS | 1 |
NCT02639546 | Phase Ib/II | Cobimetinib | Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors (iMATRIXcobi) | Completed | USA | ITA | ISR | GBR | FRA | ESP | DEU | 0 |
NCT02644460 | Phase I | Abemaciclib | Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors | Completed | USA | 0 |
NCT03654716 | Phase I | ALRN-6924 + Cytarabine ALRN-6924 | Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer | Completed | USA | 0 |
NCT03698994 | Phase II | Ulixertinib | Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03709680 | Phase I | Irinotecan + Palbociclib + Temozolomide | Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors | Active, not recruiting | USA | TUR | SWE | SVK | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BGR | BEL | ARG | 2 |
NCT03838042 | Phase Ib/II | Entinostat + Nivolumab | INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies (INFORM2 NivEnt) | Recruiting | SWE | NLD | FRA | DEU | CHE | AUT | AUS | 0 |
NCT04216953 | Phase Ib/II | Atezolizumab + Cobimetinib | MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma (COTESARC) | Active, not recruiting | FRA | 0 |
NCT04416568 | Phase II | Ipilimumab + Nivolumab | Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers | Recruiting | USA | 0 |
NCT04469530 | Phase II | Celecoxib + Cyclophosphamide + Etoposide + Sirolimus | Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors (AflacST1903) | Recruiting | USA | 0 |
NCT04897880 | Phase II | Panobinostat | A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT (NORTH) | Terminated | USA | NZL | AUS | 0 |
NCT04965753 | Phase I | FHD-609 | FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors | Terminated | USA | ITA | FRA | ESP | 0 |
NCT05064306 | Expanded access | Omburtamab I-131 | 131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults | Available | USA | 0 |
NCT05135975 | Phase II | Cabozantinib | A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors | Recruiting | USA | 0 |
NCT05286801 | Phase Ib/II | Atezolizumab + Tiragolumab | Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors | Recruiting | USA | CAN | AUS | 0 |
NCT05407441 | Phase Ib/II | Ipilimumab + Nivolumab + Tazemetostat | Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors | Recruiting | USA | 0 |
NCT05429502 | Phase Ib/II | Ribociclib + Temozolomide + Topotecan | Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | AUS | 1 |
NCT05468359 | Phase Ib/II | Atezolizumab + Bevacizumab + Cyclophosphamide + Sorafenib | Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients | Recruiting | USA | 0 |
NCT05952687 | Phase I | Idasanutlin + Selinexor | Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid Tumors | Withdrawn | 0 | |
NCT05985161 | Phase II | Selinexor | A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors | Recruiting | USA | 0 |